Clinical Trials
2.4k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1884 trials with phase data)β’ Click on a phase to view related trials
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Target Recruit Count
- 78
- Registration Number
- NCT07169318
- Locations
- πΊπΈ
Altasciences Inc - Kansas City, Overland Park, Kansas, United States
Improving Physical Ability and Cellular Senescence Elimination in HIV
- Conditions
- HIVFrailtyPrefrailAging Problems
- Interventions
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Target Recruit Count
- 80
- Registration Number
- NCT07144293
- Locations
- πΊπΈ
Alabama CRS (Site ID: 31788), Birmingham, Alabama, United States
πΊπΈUniversity of California, Los Angeles CARE Center CRS (Site ID: 601), Los Angeles, California, United States
πΊπΈUCSD Antiviral Research Center CRS (Site ID: 701), San Diego, California, United States
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Target Recruit Count
- 144
- Registration Number
- NCT07124559
- Locations
- π§πΌ
Gaborone (Site ID: 12701), Gaborone, Botswana
π§πΌMolepolole (Site ID: 12702), Gaborone, Botswana
ππΉLes Centres GHESKIO (Site ID: 30022), Port-au-Prince, Haiti
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
- Conditions
- Chronic Granulomatous Disease (CGD)
- Interventions
- Other: pCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-09-12
- Target Recruit Count
- 10
- Registration Number
- NCT07113743
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
- Conditions
- Influenza PreventionPandemic Influenza Prevention
- Interventions
- Biological: VRC-FLUMOS0122-00-VP (SteMos1) with and without Army Liposome Formulation containing saponin QS-21 (ALFQ) Adjuvant
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-09-16
- Target Recruit Count
- 56
- Registration Number
- NCT07111078
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 483
- Next
News
Single-Dose Benzathine Penicillin G Proves as Effective as Three-Dose Regimen for Early Syphilis Treatment
A randomized clinical trial of 249 participants found that a single injection of benzathine penicillin G achieved 76% serologic response compared to 70% with the three-dose regimen at 6 months.
NIH Awards $8.4 Million to OHSU Scientists to Develop HIV Cure Through Study of Three Cured Patients
Oregon Health & Science University researchers received $8.4 million from the National Institute of Allergy and Infectious Diseases to study three individuals who were cured of HIV through stem cell transplants.
Capricor Therapeutics Initiates First-in-Human Trial of StealthX Exosome-Based Vaccine Platform
Capricor Therapeutics has dosed the first subjects in a Phase 1 clinical trial of its StealthX exosome-based vaccine, marking the first-in-human evaluation of this novel platform.
Soligenix Advances SGX943 as Novel Antibiotic Alternative to Combat Drug-Resistant Bacterial Infections
Soligenix is developing SGX943 (dusquetide), a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics.
Saint Louis University Launches Phase 1 Trial for Investigational West Nile Virus Vaccine
Saint Louis University's Center for Vaccine Development will enroll up to 30 healthy adult volunteers in a Phase 1 clinical trial to evaluate the safety and immune response of an updated investigational West Nile virus vaccine.
HHS and NIH Launch "Generation Gold Standard" Universal Vaccine Platform to Combat Pandemic Threats
The U.S. Department of Health and Human Services and NIH have announced "Generation Gold Standard," a next-generation universal vaccine platform using beta-propiolactone-inactivated whole-virus technology.
Three Pharmaceutical Companies Advance Next-Generation COVID-19 Therapeutics in Clinical Trials
INOVIO Pharmaceuticals reports promising Phase I results for its DMAbs technology, showing 100% of subjects maintained relevant antibody levels with no serious adverse events.
NIH Launches First Clinical Trial of Moderna's mRNA Vaccine Against Deadly Nipah Virus
The National Institutes of Health has initiated the first human trial of Moderna's mRNA-1215 vaccine targeting Nipah virus, a deadly pathogen with a 40-70% fatality rate.
HIV Cure Trials at CROI 2025 Show Promise for Broader Patient Applications
At the 2025 Conference on Retroviruses and Opportunistic Infections (CROI), researchers presented promising results from multiple HIV cure trials, suggesting potential for wider therapeutic applications.
NIH Launches First Human Trial of LASSARAB Vaccine for Deadly Lassa Fever
The NIH has initiated a Phase 1 clinical trial of LASSARAB, a novel vaccine candidate for Lassa fever, a viral hemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of patients.